iCrowdNewswire Nov 26, 2020 7:55 AM ET
November 26. 2020 Palm Beach FL
Mira Life Science Ventures joins The Palm Beach Hedge Fund Association’s Deal Flow program
David S. Goodboy, Founder Palm Beach Hedge Fund Association stated, “It is with great pleasure that we welcome Mira Life Science Ventures to our Deal Flow platform.”
PBHFA’s Deal Flow provides companies that are seeking funds from accredited investors a platform to reach its investor membership base and network. Regulation D Rule 506(c) allows the companies to market their securities to the general public, but they must take reasonable steps to verify that all investors are accredited. The Deal Flow Pages can be viewed here
Dr. Kurt R. Gehlsen, MIRA’s Founder & CEO remarked, “we believe the business model for Mira Life Science Ventures will be attractive to many of the members of the Palm Beach Hedge Fund Association and MIRA hopes to change the paradigm for early-stage venture investing and facilitate investments into opportunities the members would never have access to”.
About MIRA Life Science Ventures
Mira Life Science Ventures was founded in 2020 by a team with over 100 years of collective experience in the life sciences – from early-stage investor/fund management to developing several approved products. Mira’s mission is to invest, incubate, and develop a new generation of innovation that will improve healthcare and patient’s lives while creating significant shareholder value long-term.
About The Palm Beach Hedge Fund Association
The Palm Beach Hedge Fund Association (PBHFA.org) is a trade organization for hedge funds, family offices, financial professionals, and ultra-high-net-worth investors in South Florida.
Since launching in the autumn of 2013 with an original core of five members, the association has grown to over 1600 members and has become the voice and go-to source for the South Florida investor & financial community.
For more information on The Palm Beach Hedge Fund Association, click here www.pbhfa.org
Keywords: biotechnology, hedge funds, private equity, pharmaceuticals, biotech investments, biotech